Format

Send to

Choose Destination
Oncotarget. 2015 Jun 10;6(16):14413-27.

Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.

Lamora A1,2,3,4, Mullard M1,2,3, Amiaud J1,2,3, Brion R1,2,3, Heymann D1,2,3, Redini F1,2,3, Verrecchia F1,2,3.

Author information

1
INSERM, UMR 957, Equipe Labellisée Ligue contre le Cancer 2012, Nantes, France.
2
Université de Nantes, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France.
3
CHU Hôtel Dieu, Nantes, France.
4
Inserm Liliane Bettencourt School, France.

Abstract

Osteosarcoma is the main malignant primary bone tumor in children and adolescents for whom the prognosis remains poor, especially when metastases are present at diagnosis. Because we recently demonstrated that TGF-β/Smad cascade plays a crucial role in osteosarcoma metastatic progression, we investigated the effect of halofuginone, identified as an inhibitor of the TGF-β/Smad3 cascade, on osteosarcoma progression. A preclinical model of osteosarcoma was used to evaluate the impact of halofuginone on tumor growth, tumor microenvironment and metastasis development. In vivo experiments showed that halofuginone reduces primary tumor growth and lung metastases development. In vitro experiments demonstrated that halofuginone decreases cell viability mainly by its ability to induce caspase-3 dependent cell apoptosis. Moreover, halofuginone inhibits the TGF-β/Smad3 cascade and the response of TGF-β key targets involved in the metastases dissemination process such as MMP-2. In addition, halofuginone treatment affects the "vicious cycle" established between tumor and bone cells, and therefore the tumor-associated bone osteolysis. Together, these results demonstrate that halofuginone decreased primary osteosarcoma development and associated lung metastases by targeting both the tumor cells and the tumor microenvironment. Using halofuginone may be a promising therapeutic strategy against tumor progression of osteosarcoma specifically against lung metastases dissemination.

KEYWORDS:

TGF-β; bone remodeling; halofuginone; metastases; osteosarcoma

PMID:
26015407
PMCID:
PMC4546476
DOI:
10.18632/oncotarget.3891
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center